The HEALOS trial testing AM-111 in sudden deafness did not meet the primary efficacy endpoint, but a subpopulation of patients with the worst hearing loss did show a statistically significant benefit.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Emerging Company Profile: Decibel Therapeutics, a Boston-based company focused on developing therapies for hearing loss, started adding its voice in an emerging development space in 2015, with the aim of becoming "the premier hearing therapies company." With ongoing research and preclinical candidates for hearing loss, Decibel is looking to secure a beneficial collaboration that will bump up its profile and give it the funding it needs to move forward.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced February through March 2016.